We simplified germline and somatic testing
Comprehensive accuracy.
From a single, trusted source.
Your patients need every step toward cancer treatment to happen quickly. So we streamlined Precise Oncology Solutions to get you all the germline and somatic insights you need to identify comprehensive treatment options, fast.
Save precious time with customized solutions, like:
- Seamless workflows tailored to your practice
- Patient education from Board-Certified Genetic Counselors who collaborate with and support your team
- Affordable options, so cost won’t be a barrier for your patients
We’ll never stop simplifying to help you and your patients make some of the most complex decisions of their lives—as fast as humanly possible.
Discover Precise Oncology Solutions
Our comprehensive portfolio of tests
[Non-FDA-Approved]
Next generation DNA-based sequencing
- Establish a thorough hereditary risk assessment to inform surgical and screening guidance
- Calculate breast cancer risk using RiskScore®, which combines Tyrer-Cuzick V8 with our polygenic risk score, calibrated to include all ancestries
[FDA-Approved]
Companion diagnostic germline testing
- Rely on DNA-based sequencing to identify breast, ovarian, pancreatic, and prostate cancer patients with germline BRCA1/2 variants who may be eligible for PARP-inhibitor therapy
Benefits of every Myriad germline test
- Obtain the lowest rate of BRCA1/2 variants of uncertain significance (1.2%) with a 48-gene panel1
- Customize our patient education to suit your practice, including pre- and post-test consultations
[FDA-Approved]
Next generation DNA-based sequencing analysis
- Identify HRD status in ovarian cancer to determine if patients may be eligible for PARP inhibitor therapy
- The only FDA-approved assay that establishes HRD status through Genomic Instability Score (GIS)—calculated utilizing loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transition (LST)
- MyChoice® CDx can identify 34% more tumors with HRD than other tumor tests that use %LOH alone2
[FDA-Approved]
[Non-FDA-Approved]
Immunohistochemical (IHC) tissue stains to assess tumor response
- Folate Receptor Alpha (FRα): FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*
- PD-L1: Offered together with Precise Tumor™ to measure protein expression and identify patients who may benefit from immunotherapy
* Mirvetuximab is a product offered by ImmunoGen, Inc.
[Non-FDA-Approved]
Next generation sequencing that evaluates DNA and RNA
- 500+ genes sequenced, including clinically actionable biomarkers for all solid tumor types
- Identify key biomarkers to determine treatment options (such as targeted therapy or immunotherapy) available for each individual cancer
- Evaluate tumor mutational burden
- Clinical trial matching
Action-ready genetic insights, to better inform treatment decisions
Develop more personalized care plans and identify which patients may benefit from surgery or PARP-inhibitor therapy. Our comprehensive genetic and genomic answers, expert clinical resources, and customized support services are here for you along each patient’s entire cancer treatment journey.
Quickly determine next steps in treatment
Surgical
Surgical Technique
Targeted Therapies
Type of Chemotherapy
PARP inhibitors can cut disease progression or death for gBRCA patients up to:
Metastatic Breast3
Pancreatic4
Ovarian5
Prostate6
Get to treatment faster with Precise Oncology Solutions
-
A single source for streamlined answers
- Address all your testing needs on one request form, with one lab
- Our streamlined online portal makes ordering as efficient as possible
- Each Summary Sheet highlights actionable results for faster review
- Our seamless workflows can be customized for your practice
- Comprehensive test findings and lifetime VUS updates inform your patient care along their entire cancer treatment journey
-
World-class clinical expertise and assistance
- Concordance checks between germline and somatic testing give you a consistent answer every time
- Access somatic, germline, and HRD status testing together with structural clinical data in our Precise™ Treatment Registry
- Receive support from best-in-class clinical experts at every step
- Customize patient education from Board-Certified Genetic Counselors who collaborate with and support your team
-
Treatment-driven results with BRCA expertise
- Rely on the first FDA-approved germline companion diagnostic for breast, ovarian, pancreatic, and metastatic prostate cancers
- Identify 34% more patients than % LOH alone for targeted therapy with our FDA-approved HRD test for ovarian cancer
- Our comprehensive, guideline-driven germline and tumor panels deliver treatment-ready results, often outlining next steps and medical management options
-
Comprehensive testing support—for all
- Personalize your pre-and post-test support in 200+ languages through our Patient Education Program
- Customize the Patient Education provided by our 50+ Board Certified Genetic Counselors—at no extra cost to you or your patients
- Lighten your team’s workload by enlisting our team to help with pre-populated test request forms, chart notes, or detailed summary notes
- Obtain reliable results for all ancestries using tests such as MyRisk with RiskScore, offering the first and only polygenic risk score to include breast density and validated for all ancestries7
-
Personalized pricing and affordable access
- Myriad is removing barriers to care with transparent cost estimates and expanded affordable options
- 60% of patients are eligible for financial assistance when needed**
- 90% of patients testing with Myriad pay $08
- 95% of private insurers cover Myriad
**Some restrictions apply; patients with government-funded programs, such as Medicaid, Medicare, Medicare-Advantage and Tricare may not be eligible.
One sheet summarizes each patient’s results
- When more than one test is ordered, a summarized sheet gives a comprehensive view of all actionable results
- Each individual test is available in full on the portal with its own easy-to-interpret results summary, to help you minimize additional review and focus on the exact details you need
One workflow for genetic and genomic insights
Easily submit orders online
Our streamlined provider portal helps to make your workflow as efficient as possible. One test request form gets you all the germline, somatic, and HRD tests you need for each patient.
Collect a germline sample
Your staff simply submits a blood or saliva sample to our lab for your patient’s germline test.
We get the tumor sample
Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for any somatic or HRD testing that is ordered.
Customized and simplified
From start to finish, our adaptable suite of workflow solutions can help your practice be more efficient, with EMR/EHR integration, setting up protocols, curating pre- and post-test consultations for your patients, summarizing test results, and more.
Myriad Collaborative Research Registry
Our registry advances patient care by providing research opportunities and fostering partnerships with clinicians. Sign up to leverage insights of combined de-identified genomic and clinical data, specifically somatic, germline, and genomic instability genetic testing combined with structural clinical data.
Examples of supported analyses include:
- Explore treatment and medical decision making across cohorts
- Expand somatic-germline interactions and associations
- Evaluate outcomes from different treatments based on ancestry, demographics, lifestyle, etc.
- Compare individual data to aggregate group datasets
Download more about Precise Oncology Solutions
HRD=homologous recombination deficiency; PARP=poly-ADP ribose polymerase; PD-L1=programmed cell death ligand 1.
References:
- Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad myRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019.
- Timms KM, et al. Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer. J. Clin. Oncol. 2020;38(15_suppl):1586-1586. doi:10.1200/jco.2020.38.15_suppl.1586.
- Robson M, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.
- Golan T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-327.
- Moore KN, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.
- Bono et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-2102.
- ASCO abstract and presentation, J. Clin. Oncol. May 28, 2021.
- Based on Myriad Genetics Internal Data. Last updated 2023.
